menu
    • menu
    [{"orgOrder":0,"company":"E-therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ETS6103","moa":"analgesics (mixed opiate receptor agonists\/antagonists)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"E-therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dexanabinol","moa":"cannabinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"E-therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"E-therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dexanabinol","moa":"cannabinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"E-therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"E-therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dexanabinol","moa":"cannabinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"E-therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"E-therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Dexanabinol","moa":"cannabinol derivatives","graph1":"Oncology","graph2":"Phase I","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"E-therapeutics \/ E-therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"E-therapeutics \/ E-therapeutics"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETX-148","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"E-therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by E-therapeutics

    Menu

    E-therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETX-148

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

                            Details : ETX-148 is a potential pan-hemophilia rebalancing agent. It utilizes e-therapeutics' GalOmic GalNAc-siRNA technology to silence novel gene targets in hepatocytes.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 05, 2025

                            Lead Product(s) : ETX-148

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

                            Details : Dexanabinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 22, 2015

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects

                            Details : Dexanabinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2014

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETS6103

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (...

                            Details : ETS6103 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 18, 2013

                            Lead Product(s) : ETS6103

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Santosh Kesari, M.D., Ph.D.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dexanabinol in Patients With Brain Cancer

                            Details : Dexanabinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 31, 2012

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Santosh Kesari, M.D., Ph.D.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            E-therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours

                            Details : Dexanabinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 12, 2011

                            Lead Product(s) : Dexanabinol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth